Literature DB >> 8925275

Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade.

S M Papa1, R C Boldry, T M Engber, A M Kask, T N Chase.   

Abstract

Dopaminoceptive system alterations in the basal ganglia have been implicated in the pathogenesis of wearing-off fluctuations that complicate levodopa therapy of Parkinson's disease. To evaluate the contribution of glutamatergic mechanisms to the associated changes in striatal efferent pathway function, we examined the ability of N-methyl-D-aspartate (NMDA) receptor blockade to modify the motor response changes produced by chronic levodopa administration to hemiparkinsonian rats. Unilaterally 6-hydroxydopamine lesioned rats, given levodopa/benserazide (25/6.25 mg/kg) twice daily for 3 weeks, developed a progressive shortening in the duration of their motor response to levodopa similar to that occurring in parkinsonian patients with wearing-off phenomenon. The acute systemic administration of MK-801 (0.1 mg/kg) to these animals completely reversed the decrease in turning duration (P < 0.01). Intrastriatal injection of the NMDA antagonist was even more effective in prolonging the levodopa response (P < 0.01), while intranigrally injected MK-801 produced no statistically significant change in the duration of levodopa-induced rotation. Rotational intensity was unaffected by all routes of MK-801 administration. These results suggest that drugs capable of blocking NMDA receptors, especially in striatum, may help ameliorate motor fluctuations in patients with advanced Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8925275     DOI: 10.1016/0006-8993(95)00924-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

Review 1.  NMDA receptors in the basal ganglia.

Authors:  P Ravenscroft; J Brotchie
Journal:  J Anat       Date:  2000-05       Impact factor: 2.610

2.  Restoration and putative protection in Parkinsonism.

Authors:  T Archer; A Fredriksson
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

3.  Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.

Authors:  A Fredriksson; W Danysz; G Quack; T Archer
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

Review 4.  The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.

Authors:  T N Chase
Journal:  Drugs       Date:  1998       Impact factor: 9.546

5.  Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane.

Authors:  A W Dunah; D G Standaert
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

Review 6.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

Review 7.  Striatal glutamatergic mechanisms and extrapyramidal movement disorders.

Authors:  Thomas N Chase; Francesco Bibbiani; Justin D Oh
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

8.  Transcriptomic approach predicts a major role for transforming growth factor beta type 1 pathway in L-Dopa-induced dyskinesia in parkinsonian rats.

Authors:  Shetty Ravi Dyavar; Lisa F Potts; Goichi Beck; Bhagya Laxmi Dyavar Shetty; Benton Lawson; Anthony T Podany; Courtney V Fletcher; Rama Rao Amara; Stella M Papa
Journal:  Genes Brain Behav       Date:  2020-09-11       Impact factor: 3.449

9.  Prolongation of levodopa responses by glycineB antagonists in parkinsonian primates.

Authors:  Stella M Papa; Yves P Auberson; J Timothy Greenamyre
Journal:  Ann Neurol       Date:  2004-11       Impact factor: 10.422

10.  Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.

Authors:  Sherri L Thiele; Betty Chen; Charlotte Lo; Tracey S Gertler; Ruth Warre; James D Surmeier; Jonathan M Brotchie; Joanne E Nash
Journal:  Neurobiol Dis       Date:  2014-08-27       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.